Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

Completed · Phase 4

Conditions studied: End-Stage Renal Disease, Hepatitis C

In brief

In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.

Key facts

Study ID: NCT02781649
Run by: Johns Hopkins University
People needed: 10
Starts: 2016-07-20
Expected to finish: 2018-01-01
Last updated by the study team: 2018-09-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants ≥ 50 years old
On the deceased donor kidney waiting list at Johns Hopkins Hospital
Awaiting a first kidney transplant
No available living kidney donors
On hemodialysis or peritoneal dialysis or stage 5 chronic kidney disease (CKD) defined as a glomerular filtration rate < 15 ml/min for ≥ past 90 days
HCV-uninfected (by both antibody and RNA PCR) and without any behavioral risk factors for contracting HCV other than being on hemodialysis.
Calculated panel reactive anti-human leukocyte antigen (HLA) antibody (cPRA) below 20 percent
Female who is:
practicing total abstinence from sexual intercourse (minimum 1 complete menstrual cycle)
sexually active with female partners only
not of childbearing potential: defined as postmenopausal for at least 2 years prior to screening defined as amenorrheic for longer than 2 years, age appropriate, and confirmed by a follicle-stimulating hormone level indicating a postmenopausal state, or surgically sterile: defined as bilateral tubal ligation, bilateral oophorectomy or hysterectomy or has a vasectomized partner(s);
of childbearing potential and sexually active with male partner(s): currently using at least one effective method of birth control at the time of screening and agree to practice two effective methods of birth control while receiving study drug (as outlined in the participant information and consent form starting with Study Day 1 and for 30 days after stopping study drug, or for 6 months after stopping study drug if receiving RBV (Note: Estrogen-containing hormonal contraceptives, including oral, injectable, implantable, patch and ring varieties, may not be used during study drug treatment).
Males who are not surgically sterile and are sexually active with female partner(s) of childbearing potential must agree to practice two effective forms of birth control (as outlined in the participant information and consent form) throughout the course of the study, starting with starting with Study Day 1 and for 30 days after stopping study drug, or for 6 months after stopping study drug if receiving ribavirin (RBV)

You may not qualify if…

Plan to receive a multi-organ transplant
Plan to receive a dual kidney transplant (including en bloc)
Prior solid organ transplant
Participating in another study that involves an intervention or investigational product
Plan to receive a blood type incompatible kidney
History of human immunodeficiency (HIV), hepatitis C (HCV), or active hepatitis B (HBV) infection defined as being on active antiviral treatment for HBV, detectable hepatitis B surface Ag or detectable hepatitis B DNA
Active or unresolved bacterial, viral, or fungal infection that is clinically significant
History of cirrhosis or pre-existing liver disease such as non-alcoholic steatohepatitis
History of illicit drug use or alcohol abuse within 12 months prior to screening
Psychiatric or physical illness that in the opinion of the investigator would make it unsafe to proceed with transplantation or interfere with the ability of the subject to participate in the study.

Where it is running

Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.